<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucl Recept Signal</journal-id><journal-id journal-id-type="iso-abbrev">Nucl Recept Signal</journal-id><journal-id journal-id-type="publisher-id">NRS</journal-id><journal-title-group><journal-title>Nuclear Receptor Signaling</journal-title></journal-title-group><issn pub-type="epub">1550-7629</issn><publisher><publisher-name>Nuclear Receptor Signaling Atlas</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25422594</article-id><article-id pub-id-type="publisher-id">nrs12004</article-id><article-id pub-id-type="doi">10.1621/nrs.12004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Inactivation of RAR&#x003b2; inhibits Wnt1-induced mammary tumorigenesis by
suppressing epithelial-mesenchymal transition</article-title><alt-title alt-title-type="left-running">Running Head: RAR&#x003b2; and EMT</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xingxing</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gigu&#x000e8;re</surname><given-names>Vincent</given-names></name></contrib><aff id="aff1">Goodman Cancer Research Centre, 1160 Pine Avenue West, McGill University,
Montr&#x000e9;al, Qu&#x000e9;bec H3A 1A3 (XL, VG) and Departments of Biochemistry, Medicine and
Oncology, 3655 Promenade Sir William Osler, McGill University, Montr&#x000e9;al, Qu&#x000e9;bec H3G
1Y6 (VG), <country>Canada</country>.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding Author: VG, <email xlink:href="vincent.giguere@mcgill.ca">vincent.giguere@mcgill.ca</email></corresp><fn id="afn1"><p>Public Datasets: NCBI Gene Expression Omnibus database (GEO, GSE56391)</p></fn><fn id="afn2"><p>Author Contributions: XL carried out the molecular and genetic studies, participated in the
design of the study, performed the statistical analysis and helped to draft the manuscript. VG
conceived of the study, participated in its design and coordination and wrote the manuscript. The
two authors read and approved the final manuscript.</p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>4</day><month>11</month><year>2014</year></pub-date><volume>12</volume><elocation-id>e004</elocation-id><history><date date-type="received"><day>2</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>18</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 Liu and Gigu&#x000e8;re</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Liu and Giguere et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Non-Commercial
Attribution License, which permits unrestricted non-commercial use distribution and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><p>Retinoic acid receptor &#x003b2; (RAR&#x003b2;) has been proposed to act as a tumor suppressor in
breast cancer. In contrast, recent data have shown that RAR&#x003b2; promotes ERBB2-induced mammary
gland tumorigenesis through remodeling of the stromal compartment and activation of
cancer-associated fibroblasts. However, it is currently unknown whether RAR&#x003b2; oncogenic
activity is specific to ERBB2-induced tumors, or whether it influences the initiation and
progression of other breast cancer subtypes. Accordingly, we set out to investigate the involvement
of RAR&#x003b2; in basal-like breast cancer using mouse mammary tumor virus (MMTV)-wingless-related
integration site 1 (Wnt1)-induced mammary gland tumorigenesis as a model system. We found that
compared with wild type mice, inactivation of <italic>Rarb</italic> resulted in a lengthy delay in
<italic>Wnt1</italic>-induced mammary gland tumorigenesis and in a significantly slower tumor growth
rate. Ablation of <italic>Rarb</italic> altered the composition of the stroma, repressed the
activation of cancer-associated fibroblasts, and reduced the recruitment of inflammatory cells and
angiogenesis. Reduced expression of IGF-1 and activity of its downstream signaling pathway
contribute to attenuate EMT in the <italic>Rarb</italic>-null tumors. Our results show that, in the
absence of retinoid signaling via RAR&#x003b2;, reduced IGF-1 signaling results in suppression of
epithelial-mesenchymal transition and delays tumorigenesis induced by the <italic>Wnt1</italic>
oncogene. Accordingly, our work reinforces the concept that antagonizing RAR&#x003b2;-dependent
retinoid signaling could provide a therapeutic avenue to treat poor outcome breast cancers.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Breast cancer</kwd><kwd>IGF-1</kwd><kwd>nuclear receptor</kwd><kwd>oncogene</kwd><kwd>retinoid</kwd></kwd-group></article-meta><notes><def-list list-type="simple" list-content="abbreviations"><title>Abbreviations: </title><def-item><term>AKT</term><def><p>thymoma viral proto-oncogene 1</p></def></def-item><def-item><term>CAFs</term><def><p>cancer associated fibroblasts</p></def></def-item><def-item><term>EMT</term><def><p>epithelial mesenchymal transition</p></def></def-item><def-item><term>GITC</term><def><p>guanidinium isothiocyanate</p></def></def-item><def-item><term>IGF-1</term><def><p>insulin-like growth factor-1</p></def></def-item><def-item><term>IHC</term><def><p>immunohistochemistry</p></def></def-item><def-item><term>LCM</term><def><p>laser capture microdissection</p></def></def-item><def-item><term>MMTV</term><def><p>mouse mammary tumor virus</p></def></def-item><def-item><term>RA</term><def><p>retinoic acid</p></def></def-item><def-item><term>RAR&#x003b2;</term><def><p>retinoic acid receptor &#x003b2;</p></def></def-item><def-item><term>RT-PCR</term><def><p>reverse transcription-polymerase chain reaction</p></def></def-item><def-item><term>Wnt-1</term><def><p>wingless-related MMTV integration site 1</p></def></def-item></def-list></notes></front><body><sec sec-type="intro"><title>Introduction</title><p>Retinoic acid (RA), which is derived from dietary vitamin A, plays an essential role in the
maintenance of the differentiated state of epithelial cells and tissue remodeling [<xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r3" ref-type="bibr">3</xref>]. The family of retinoic
acid receptors (RARs) that includes the RAR&#x003b1;, &#x003b2; and &#x003b3; subtypes and associated
alternatively spliced isoforms are the main mediators for the biologic effects of RA [<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref>]. RA and other natural and
synthetic RAR agonists are well known to inhibit the growth of human breast tumor cell lines
<italic>in vitro</italic> and in mouse xenograft models, a process that generally involves the
induction of both apoptosis and cell-cycle arrest [<xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r12" ref-type="bibr">12</xref>]. In addition, the absence of RAR&#x003b2;-dependent retinoid
signaling has been associated with the development of carcinomas, including breast cancer, and
resistance to the anti-cancer activity of RA [<xref rid="r13" ref-type="bibr">13</xref>]. Despite
the potent growth-suppressing activity of retinoids on human breast cancer cell lines, this class of
compounds has not shown relevant anti-cancer activity in the treatment of breast cancer [<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>].</p><p>Recently, RAR-null mice have been used to address the role of the RARs in mammary gland
development and the response of the gland to specific oncogenic insults [<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>]. Ablation of RAR&#x003b1;1 led to an
increase in the density of the mammary epithelial tree and the content of luminal mammary
progenitors, in addition to reducing the size of the mammary stem cell-containing compartment [<xref rid="r17" ref-type="bibr">17</xref>]. In contrast, loss of RAR&#x003b2; resulted in a delay in
mammary tree development in the pubertal stage as a significant shortening of the distance between
the lymph node and the terminal end buds were observed in the RAR&#x003b2;-null gland [<xref rid="r16" ref-type="bibr">16</xref>]. The developmental abnormalities observed in both RAR-deficient
mouse models were transient since, as previously reported [<xref rid="r18" ref-type="bibr">18</xref>-<xref rid="r20" ref-type="bibr">20</xref>], the glands were fully functional at later
stages of development. While ablation of RAR&#x003b1;1 and &#x003b2; resulted in distinct
developmental mammary gland abnormalities, the absence of RA signaling transduced by either receptor
resulted in a delay in mammary gland tumorigenesis. In the RAR&#x003b1;1-null model, the reduction
observed in the mammary stem cell-containing compartment might be a factor in the delay in tumor
formation by the <italic>Wnt1</italic> oncogene, but the exact mechanism responsible for the
pro-oncogenic property of RAR&#x003b1;1 in this context remains to be determined. On the other hand,
absence of RAR&#x003b2; led to a remodeling of the stroma during tumor progression induced by the
<italic>Erbb2</italic> oncogene that was marked by a decrease in angiogenesis, in the recruitment of
inflammatory cells and in the number of myofibroblasts [<xref rid="r16" ref-type="bibr">16</xref>].
In agreement with this observation, tissue recombination experiments demonstrated that the presence
of RAR&#x003b2; in the stromal compartment is essential for the growth of mammary carcinoma, and that
RA-dependent activity of the Cxcl12/Cxcr4/Erbb2 signaling axis played a significant role in this
process. Together, these studies suggest that retinoid-based approaches for the prevention and
treatment of breast cancer should be re-evaluated and that a better understanding of the mechanisms
of retinoid action in mammary gland tumorigenesis is required to achieve this goal.</p><p>In the current study, we further tested the specificity of the RAR/oncogene interaction in the
development of mammary gland carcinoma using bigenic mice generated by crossing the RAR&#x003b2;-null
mice with the MMTV-<italic>Wnt1</italic> transgenic mice. The <italic>Wnt1</italic> oncogene targets
mammary stem cells or early progenitor cells as transformation cells [<xref rid="r21" ref-type="bibr">21</xref>]. Accordingly, <italic>Wnt1</italic>-induced tumors show a co-existence of both
luminal cells and basal/myoepithelial cells, which is reminiscent of human basal-like breast cancer
that is associated with poor prognosis and lack of effective treatment [<xref rid="r22" ref-type="bibr">22</xref>]. <italic>Wnt1</italic>-induced tumors have also been reported to have abundant
activated stroma that correlated with more aggressive tumor development [<xref rid="r23" ref-type="bibr">23</xref>]. Therefore, we sought to investigate the influence of RAR&#x003b2; on
<italic>Wnt1</italic>-induced mammary carcinoma. We found that inactivation of RAR&#x003b2; resulted
in a protective effect against <italic>Wnt1</italic>-induced mammary gland tumorigenesis, abrogation
of Wnt signaling in both the epithelial and stromal compartments, and suppression of
epithelial-mesenchymal transition (EMT) in the tumors. Our work indicates therefore that RAR&#x003b2;
is essential for the bi-directional interaction between tumor and stromal cells and that RAR&#x003b2;
specific antagonists may represent a novel therapeutic strategy to treat poor outcome breast
cancer.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Mice</title><p>All animals were FVB/NJ background and housed in a pathogen-free facility at McGill University
and were given a standard rodent diet and water ad libitum. MMTV-<italic>Wnt1</italic> mice were
purchased from the Jackson Laboratory [<xref rid="r24" ref-type="bibr">24</xref>]. To determine the
initiation of mammary tumor formation, mice were palpated weekly (sensitive to 1-mm tumor masses).
All mouse manipulations were performed in accordance with the McGill Facility Animal Care Committee
and the Canadian Council on Animal Care.</p></sec><sec><title>Cell culture</title><p>Mouse mammary fibroblast cell lines were generated from the MMTV-<italic>Wnt1</italic> animals as
described before [<xref rid="r16" ref-type="bibr">16</xref>]. To generate tumor cells, tumors were
dissected, mechanically dissociated, and forced through 40 &#x003bc;m mesh. Viable cells were plated,
grown in DMEM supplemented with 10% FBS and penicillin/streptomycin. The cells had virtually
identical epithelial morphology under microscope and had similar cell surface marker expression. All
cultured cells were maintained in DMEM supplemented with 10% FBS and incubated in 5% CO<sub>2</sub>
at 37<sup>o</sup>C. The fibroblasts were treated with all-trans RA (Sigma #R2625) at a concentration
of 0.5 &#x003bc;M for 2 days to generate conditioned media. Conditioned media from
<italic>Rarb</italic>-null or wild-type mouse mammary gland fibroblasts were also supplemented with
either IGF-1 or anti-IGF-1 antibody (R&#x00026;D Systems) at final concentrations of 10 ng/ml and 40
&#x003bc;g/ml, respectively.</p></sec><sec><title>Reactive stroma index</title><p>Hematoxylin and eosin staining was carried out in the histology service core of the Goodman
Cancer Research Centre. Stained sections were examined in a blinded manner and scored for the
reactive stroma index based on the percentage contribution of a stroma area in tumor mass (i.e.,
0&#x02013;10% stroma area = 0, 11&#x02013;20% stroma area = 1, and so on, &#x0003e;50% stroma area = 5).
The average of five areas was used as the reactive stroma index for each sample.</p></sec><sec><title>Histological analyses</title><p>Immunohistochemical analyses were performed on 4-&#x003bc;m formalin-fixed paraffin-embedded
sections of tumors from mice killed one month after tumor initiation. Immunostaining was done using
the VECTASTAIN avidin-biotin complex kit (Vector Laboratories) as previously described [<xref rid="r25" ref-type="bibr">25</xref>]. Immunofluorescence staining was conducted on formalin-fixed
paraffin-embedded tumor sections. Five random areas per section from 3 separate sections obtained
from different mice for each group were analyzed. The following dilutions of primary antibodies were
used: rabbit polyclonal anti&#x02013;human-RAR&#x003b2; (Abcam), 1:100; mouse monoclonal anti-human
Ki67 (clone B56; BD Pharmingen), 1:100; rabbit polyclonal anti-mouse Wnt1 (Upstate), 1:50; rabbit
polyclonal anti&#x02013;human-caspase-3 (Cell Signaling), 1:50; rat monoclonal anti&#x02013;mouse-CD31
(clone Mec13.3; Biocare), 1:50; mouse monoclonal anti-CD45, 1:100, and rabbit polyclonal anti-mouse
collagen I, 1:100 (Abcam Inc.), horse polyclonal anti-human smooth muscle actin-&#x003b1;
(&#x003b1;-SMA) (Abcam), 1:100, ; rabbit polyclonal anti-mouse IGF1 (Abcam), 1:100. For the negative
control, primary antibody was replaced with non-immunized rabbit or mouse IgG (Vector Laboratories).
All images were taken with 10&#x000d7; objectives (100&#x000d7; magnification). For multiple antigen
labeling the VECTASTAIN System (Vector ABCDAB kit, Vector ABC-AP kit, and Vector ImmPRESSNovaRED and
VIP kit) (Vector Laboratories) was used. Peroxidase and alkaline phosphatase substrates were used to
develop color of the antigens with different localization. To compare positive cell numbers, 10
random fields per section were documented in the Aperio Image System and were analyzed using the
Spectrum software (Aperio Technologies). Mean values shown beside the corresponding images were
determined from results from at least six different mice for each genotype.</p></sec><sec><title>Apoptosis analysis</title><p>The number of TUNEL-positive or caspase 3-postive tumor cell nuclei was calculated relative to
the total number of 1,000 cancer cell nuclei, which was analyzed with the Spectrum software. Mean
values were determined from results from at least six different mice.</p></sec><sec><title>Western blotting</title><p>Lysates were prepared from the mammary tumors of three <italic>Rarb</italic><sup>-/-</sup> and
three wild-type mice. Antibodies against phospho-GSK3&#x003b2; (Ser9, 07-835), GSK3&#x003b2;
(07-1413), Snail (ABD38), phospho-AKT (9611), and AKT (9272) were purchased from Cell Signaling
Technology. Antibodies against RAR&#x003b2; (SC-552), Wnt-1 (SC-5630), Wisp1 (SC-13316), E-cadherin
(SC-7870), integrin &#x003b1;5 (SC-10719), LAMA1 (SC-56145), vimentin (SC-373717), cytokeratin
(SC-529), IGF1 (SC-7144), IGFBP5 (SC-6006), and actin (SC-1616) were purchased from Santa Cruz
Biotechnology.</p></sec><sec><title>Laser capture microdissection, RNA extraction and linear amplification</title><p>All tissues included in this study were re-examined by an animal pathologist dedicated to the
project. Tissue specimens were micro-dissected into epithelium and stroma using a PixCell IIe laser
micro-dissection (LCM) system (Arcturus). All micro-dissections were performed within two hours
following tissue staining. Total RNA was extracted from each population of micro-dissected cells
using a guanidinium isothiocyanate (GITC) extraction protocol. Briefly, LCM caps were incubated for
5 minutes (room temperature) in 200 &#x003bc;l GITC extraction buffer (4 M GITC, 25 mM sodium citrate
pH 7.0, 0.1 M &#x003b2;-mercaptoethanol, 0.5% N-lauroylsarcosine) supplemented with 1.6 &#x003bc;l
&#x003b2;-mercaptoethanol. Subsequently, 20 &#x003bc;l of 2 M NaOAc, pH 4.0, 220 &#x003bc;l of
water-saturated phenol and 60 &#x003bc;l of chloroform-isoamyl alcohol (23:1) were added to the
extraction buffer. Following a 15 minute incubation on ice and centrifugation (12,000 rpm, 15
minutes) the aqueous phase was removed and RNA was precipitated with 2 &#x003bc;l glycogen
(GenHunter, Nashville, Tennessee, USA) and 200 &#x003bc;l isopropanol. Samples were placed at -
80&#x000b0;C for 30 minutes and centrifuged at 4&#x000b0;C (12,000 rpm) for 30 minutes to pellet RNA.
Pellets were washed with 70% ethanol, air-dried and subjected to DNase I treatment (Roche, Basel,
Switzerland). DNAse treatment was performed in the presence of an RNase inhibitor (Invitrogen,
Carlsbad, California, USA). Subsequently, samples were re-extracted as described above and
re-suspended in 10 &#x003bc;l of diethylpyrocarbonate-treated water. RNA was quantified using a
RiboGreen assay (Molecular Probes, Carlsbad, California, USA). Subsequently, 2 to 4 ng of total RNA
was subjected to two rounds of T7 linear amplification using Ambion Amino Allyl MessageAmp kit
(Ambion, Austin, Texas, USA) and labeled with Cy3 and Cy5 dyes according to the manufacturer's
procedure. Prior to microarray hybridizations, amplified products were quantified using a
spectrophotometer (Nanodrop, Wilmington, Delaware, USA) and analyzed using a BioAnalyzer to assay
for quality (Agilent Technologies, Santa Clara, California, USA).</p></sec><sec><title>RNA microarrays</title><p>SurePrint G3 mouse Genome 8x60 K arrays (Agilent Technologies, product G4852A) were used for all
experiments. RNA samples (500 ng) were subjected to fragmentation followed by 18 hours
hybridization, washing, and scanning (Agilent Technologies, model G2505B) according to the
manufacturer's protocol (manual ID #G4140-90030). Samples were hybridized against Universal
mouse Reference RNA (Stratagene, ID #750600, La Jolla, California, USA). Duplicate hybridizations
were performed for all samples using reverse-dye labeling. Microarray data were feature extracted
using Feature Extraction Software (v. 7.11) from Agilent with the default parameters. Raw data were
uploaded to the NCBI Gene Expression Omnibus database (GEO, GSE#56391). Outlier features on arrays
were flagged by the software. Arrays were required to have an average raw signal intensity of 1,000
in each channel, and a signal to noise ratio above 16 per channel. MvA plots were examined for signs
of hybridization or labeling problems. Replicate arrays were required to have a concordance above
0.944. This level was established empirically using sets of known good replicate arrays in our
database.</p></sec><sec><title>Real-time PCR for Igf1 expression</title><p>Total RNA from LCM samples was amplified using Amino Allyl MessageAmp II aRNA Kit (Ambion #1753).
cDNA was made from 2 &#x003bc;g of RNA by reverse transcription with Oligo(dT) primer, dNTPs, 5X 1st
strand buffer, DTT, RNase inhibitor, and Superscript II RNase H Reverse Transcriptase (Invitrogen).
cDNA was amplified by qRT-PCR using the specific forward 5&#x02019;-TTCTACCTGGCGCTCTGCTTGC and
reverse 5&#x02019;-CCCTCCGAATGCTGGAGCCATA primers, a QuantiTect SYBR Green PCR Kit (Qiagen) and a
LightCycler instrument (Roche) following the Qiagen software protocol.</p></sec><sec><title>ELISA</title><p>Submandibular venous blood was collected into microcentrifuge tubes using a sterile lancet
(Medipoint, Mineola, NY) according to the manufacturer&#x02019;s instructions. Whole blood was
centrifuged at 2500&#x000d7;<italic>g</italic> for 20 minutes at 4&#x000b0;C to collect serum, which
was then stored at &#x02212;80&#x000b0;C. Serum was processed for ELISA of IGF-1 (R&#x00026;D Systems,
Minneapolis, MN) according to the manufacturer&#x02019;s protocol. Serum IGF-1 levels are reported in
ng/ml. An IGF-1 control sample, with aliquots stored at -80&#x000b0;C, was included on each plate,
and all data are reported using simple ratio normalization to the initial reading of the control
sample.</p></sec><sec><title>Statistical analysis</title><p>Two-tailed paired Student <italic>t</italic> test was calculated by Excel software. Prism
software was used for one or 2-way ANOVA and log-rank (Mantel-Cox) test.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Global ablation of Rarb in mice delays Wnt1-induced mammary gland tumorigenesis and alters
the stromal compartment</title><p>To further study the potential role of RAR&#x003b2; as a tumor promoter in mammary gland
tumorigenesis, we used the well-characterized mouse model of human breast cancer expressing the
oncogene <italic>Wnt1</italic> in combination with the <italic>Rarb</italic>-null allele [<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r24" ref-type="bibr">24</xref>]. While both
<italic>Rarb</italic><sup>-/-</sup> and wild-type mice displayed similar high penetrance for tumor
formation (78% and 83%, respectively), the <italic>Rarb</italic><sup>-/-</sup> mice showed a
significant delay (~12 weeks, P&#x0003c;0.01) in tumor formation when strong expression of
<italic>Wnt1</italic> was driven by the MMTV promoter (<xref ref-type="fig" rid="f1">Figure
1A</xref>). In addition, the tumors in mice with the <italic>Rarb</italic><sup>-/-</sup> genetic
background grew at a significantly slower rate than tumors induced in their wild-type siblings (6.3
vs 4.0 weeks, P&#x0003c;0.05) (<xref ref-type="fig" rid="f1">Figure 1B</xref>). Consistent with these
results, examination of mammary gland sections taken from MMTV-<italic>Wnt1</italic> mice by
immunohistochemistry (IHC) showed a significant decrease in Ki67 labeling in
MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup> tumor cells compared to
MMTV-<italic>Wnt1</italic> wild type tumor cells (<xref ref-type="fig" rid="f1">Figure 1C</xref>).
On the other hand, TUNEL staining showed significantly increased apoptotic cell death in the tumors
growing in <italic>Rarb</italic>-null animals (<xref ref-type="fig" rid="f1">Figure 1D</xref>).
Concurrently, caspase 3 IHC also displayed more apoptotic enzyme activity in
<italic>Rarb</italic>-null tumor cells (<xref ref-type="fig" rid="f1">Figure 1E</xref>). As the
absence of RAR&#x003b2; had a major impact on the composition of the stroma surrounding ERBB2-induced
mammary tumors [<xref rid="r16" ref-type="bibr">16</xref>], we next measured the grade of stromal
activation in <italic>Wnt1</italic>-induced tumors generated in the
<italic>Rarb</italic><sup>-/-</sup> and wild type genotypes. Indeed, the MMTV-<italic>Wnt1</italic>
tumors in the wild type background had a 31% higher reactive stroma index than tumors developing in
<italic>Rarb</italic>-null siblings (3.8&#x000b1;0.7 vs 2.9&#x000b1;1.1 P&#x0003c;0.05) (<xref ref-type="fig" rid="f1">Figure 1F</xref>). To determine whether the absence of RAR&#x003b2; affected
the growth potential of cancer associated fibroblasts (CAFs), we generated stromal fibroblasts from
control and <italic>Rarb</italic><sup>-/-</sup> mammary glands as previously described [<xref rid="r16" ref-type="bibr">16</xref>] and compared their growth rate <italic>in vitro</italic>. In
low serum conditions (2% FBS), the <italic>Rarb</italic><sup>-/-</sup> fibroblasts displayed growth
arrest whereas wild type fibroblasts survived and divided indicating that
<italic>Rarb</italic><sup>-/-</sup> CAFs have less aggressive malignant properties that persists
<italic>ex vivo</italic> (<xref ref-type="fig" rid="f1">Figure 1G</xref>).</p><fig id="f1" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Ablation of <italic>Rarb</italic> suppresses Wnt1-induced mammary tumorigenesis and affects
the composition of the stroma.</title><p>(a) <italic>Rarb</italic>-null mice show a significant delay in tumor formation when the
expression of <italic>Wnt1</italic> is driven by the MMTV-LTR promoter (n=25
<italic>Rarb</italic><sup>-/-</sup> and 26 wild-type mice). Insets: Western blot analysis of
RAR&#x003b2; and Wnt1 expression in wild-type and <italic>Rarb</italic><sup>-/-</sup> mice;
immunostaining of RAR&#x003b2; in tumor (T) and stroma (S) in wild-type tissue. (b) Tumor growth rate
as measured as time to end point (tumor burden total of 2 cm<sup>3</sup>), n=24. (c) Cell
proliferation rate was identified by Ki67 expression (red signal), which is significantly lower in
the tumors from <italic>Rarb</italic> null mice. (d) TUNEL analysis showed significantly increased
apoptotic cells in <italic>Rarb</italic> null mice. (e) Caspase 3 is detected in tumor cells with a
significant increase in <italic>Rarb</italic> null animals. (f) Mammary tumor paraffin sections
stained for collagen 1 (Col3a1) show a decrease in matrix stiffness. Quantification of reactive
stroma index (RSI) is shown on the right panel. (g) Growth rate of CAFs generated from control and
<italic>Rarb</italic>-null mammary glands <italic>in vitro</italic>.. For panels c, d and e, scale
bars, 50 and 20 &#x003bc;m for low (left) and high magnification (right), respectively. For panel f,
scale bar, 50 &#x003bc;m. *<italic>P</italic> &#x0003c; 0.05, **<italic>P</italic> &#x0003c; 0.01,
***<italic>P</italic> &#x0003c;0.001</p></caption><graphic xlink:href="nrs-12-004-g1"/></fig></sec><sec><title>Loss of <italic>Rarb</italic> results in remodeling of the stromal compartment in
Wnt1-induced mammary gland tumors</title><p>Stroma may initiate a desmoplastic reaction that includes activation of CAFs and
trans-differentiation of tumor or epithelial cells into myofibroblasts, infiltration of immune
cells, increased secretion of growth factors and cytokines as well as elevated matrix synthesis and
remodeling that manifests as matrix stiffening. Analysis of differential gene expression in the
stroma and epithelial compartments using laser capture microdissection (LCM) showed that several
genes associated with activation of fibroblasts such as <italic>Col3a1</italic>,
<italic>Col5a1</italic>, <italic>Col5a3</italic>, <italic>Col6a2</italic>, <italic>Col6a3</italic>,
<italic>Fn1</italic>, <italic>Fap</italic> and <italic>Vim</italic> are down-regulated in the
stromal compartment of MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup> animals
compared to their wild type siblings (<xref ref-type="fig" rid="f2">Figure 2A</xref>).
Morphologically, IHC analysis indicated reduced collagen deposition in
MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup> tumor sections (<xref ref-type="fig" rid="f2">Figure 2B</xref>), indicating decreased matrix stiffening. Moreover, significantly
decreased smooth muscle actin (&#x003b1;-SMA) positive cells were found in
MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup> tumor sections (<xref ref-type="fig" rid="f2">Figure 2C</xref>), further indicating that fibroblast activation was suppressed in these
animals. In addition, a reduction in the recruitment of inflammatory cells as measured by CD45
staining was observed in the peritumoral stroma of <italic>Rarb</italic>-null mice relative to their
wild type siblings (<xref ref-type="fig" rid="f2">Figure 2D</xref>). LCM-RNA microarray data also
showed that several genes involved in angiogenesis, including <italic>Angpt2</italic>,
<italic>Angptl4</italic> and <italic>Bmper</italic>, were down regulated in the stroma of
MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup> animals (<xref ref-type="fig" rid="f2">Figure 2A</xref>). Consistent with the gene expression data, non-uniformly distributed
blood vessels with irregular shape were observed in sections obtained from the mammary tumors of
wild type mice and stained for CD31 expression (<xref ref-type="fig" rid="f2">Figure 2E</xref>).
These abnormal blood vessels were inappropriately branched, dilated and usually ended blindly. In
contrast, we found significantly fewer blood vessels in the <italic>Rarb</italic>-null tumors.</p><fig id="f2" fig-type="figure" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Loss of <italic>Rarb</italic> alters the gene expression profile of the stromal compartment
and its composition.</title><p>(a) Differential gene expression analysis of the microdissected stromal compartment of
MMTV-<italic>Wnt1</italic> and MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup>
tumors. Data are presented as relative fold change (log2) <italic>vs.</italic> wild-type stroma. (b)
Mammary tumor paraffin sections stained for collagen 1 (COL3A1) show a decrease in matrix stiffness
and indicate reduced activity of the CAFs in the <italic>Rarb</italic>-null tumor microenvironment.
Quantification of positive area is shown on the right panel. (c) Paraffin sections stained for
&#x003b1;-SMA (red, cytoplasmic). Quantification of positive area is shown on the right. (d) Mammary
tumor paraffin sections stained for CD45 demonstrate a decreased infiltration of inflammatory cells
in the <italic>Rarb</italic>-null stroma. Quantification of positive cells is shown on the right
panel. (e) Mammary tumor paraffin sections stained for CD31 demonstrate a reduction of angiogenesis
in the <italic>Rarb</italic>-null tumor microenvironment. Quantification of positive area is shown
on the right panel. For all panels, scale bars, 50 and 20 &#x003bc;m for low (left) and high
magnification (right), respectively.</p></caption><graphic xlink:href="nrs-12-004-g2"/></fig></sec><sec><title>Inhibition of epithelial-mesenchymal transition in Wnt1-induced <italic>Rarb</italic>-null
tumors</title><p>Besides activation from local fibroblasts, emerging evidence indicates that matrix-producing
myofibroblasts also arise through epithelial-mesenchymal transition (EMT) [<xref rid="r26" ref-type="bibr">26</xref>]. Interestingly, LCM-mRNA microarray data showed that several genes involved in
EMT, such as <italic>Ecm2</italic>, <italic>Mmp3</italic>, <italic>Fgf2</italic>, and
<italic>Igf1</italic>, were significantly down regulated in
MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup> tumors (<xref ref-type="fig" rid="f3">Figure 3A</xref>). We observed that the expression of markers of epithelium undergoing EMT,
including E-cadherin, cytokeratin and laminin, were significantly increased at the protein level,
whereas the expression of vimentin and integrin (ITGA5) were decreased in
MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup> animals (<xref ref-type="fig" rid="f3">Figure 3B</xref>). This observation was further confirmed by immunofluorescence showing
higher E-cadherin levels in sections obtained from <italic>Rarb</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="f3">Figure 3C</xref>), as well as increased translocation of &#x003b2;-catenin
into the nucleus in wild type cells (<xref ref-type="fig" rid="f3">Figure 3D</xref>). Collectively,
these data indicate that <italic>Rarb</italic> ablation results in suppression of EMT in the
<italic>Wnt1</italic>-induced tumors.</p><fig id="f3" fig-type="figure" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Inhibition of epithelial-mesenchymal transition in Wnt1-induced <italic>Rarb</italic>-null
tumors.</title><p>(a) Differential gene expression analysis of the microdissected epithelial compartment of
MMTV-<italic>Wnt1</italic> and MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup>
tumors. Data are presented as relative fold change (log2) <italic>vs.</italic> wild-type stroma. (b)
Western blot analysis of markers of epithelium undergoing EMT in lysates derived from
MMTV-<italic>Wnt1</italic> and MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup>
tumors. (c) Expression of E-cadherin (red) and Ki67 (green) as monitored by immunofluorescence in
MMTV-<italic>Wnt1</italic> and MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup>
tumors. (d) Nuclear localization of &#x003b2;-catenin (green) as monitored by immunofluorescence.</p></caption><graphic xlink:href="nrs-12-004-g3"/></fig></sec><sec><title>Down regulation of the IGF1/AKT axis in Wnt1-induced <italic>Rarb</italic>-null
tumors</title><p>IGF-1 plays a central role in cell growth, differentiation, survival, transformation and
metastasis, and deregulation of the IGF signaling pathway is well recognized as a key contributor to
the progression of multiple cancers including mammary gland tumors. The IGF-1 signaling axis can
also affect EMT. IGF-1 binds IGF1R to induce PI3K and activates AKT to repress GSK3&#x003b2;.
GSK3&#x003b2; is a repressor of &#x003b2;-catenin and Snail able of inhibiting E-cadherin expression
and subsequently promotes EMT and tumor progression. While we observed a reduction in the expression
of <italic>Igf1</italic> in the tumor compartment, IGF-1 is also produced by stromal cells. Western
blotting using protein lysates obtained from whole tumors showed a decrease in endogenous IGF-1
levels and an increase in the expression of <italic>IGFBP5</italic>, an antagonist of IGF signaling,
in the <italic>Rarb</italic>-null samples (<xref ref-type="fig" rid="f4">Figure 4A</xref>). We next
investigated whether the reduced levels of IGF-1 had an impact on AKT expression and activity in the
tumors. Indeed, tumors obtained from MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup>
animals displayed a small decrease in total AKT levels and a sharp reduction of phosphorylated AKT
at serine 473 (<xref ref-type="fig" rid="f4">Figure 4A</xref>). In addition, we found increased
phosphorylation of GSK3&#x003b2; and decreased expression of Snail, both of which are downstream
components of the IGF-1/AKT axis (<xref ref-type="fig" rid="f4">Figure 4A</xref>). While no
significant difference in the serum concentration of IGF-1 between <italic>Rarb</italic>-null
animals and their wild type siblings was detected by ELISA (<xref ref-type="fig" rid="f4">Figure
4B</xref>), we found significantly lower IGF-1 concentrations in the supernatants collected from
<italic>Rarb</italic>-null CAFs in culture compared to the supernatants obtained from wild type
fibroblasts (<xref ref-type="fig" rid="f4">Figure 4C</xref>). These results indicate that changes in
local IGF-1 levels are not due to a systemic effect of the absence of RAR&#x003b2; but intrinsic to
the tumor microenvironment. Furthermore, retinoic acid induced the expression of IGF-1 mRNA from
wild type fibroblasts (<xref ref-type="fig" rid="f4">Figure 4D</xref>). Finally, tumor cells
isolated from the <italic>Wnt1</italic>-induced tumors in wild type mice were cultured in the
presence of conditioned media obtained from <italic>Rarb</italic>-null and wild type CAFs to measure
growth rate. <italic>Wnt1</italic>-induced tumor cells cultured in the presence of conditioned media
derived from <italic>Rarb</italic>-null fibroblasts showed a significant decreased cell growth rate
(<xref ref-type="fig" rid="f4">Figure 4E</xref>). In addition, immune-neutralization of IGF-1 in the
conditioned medium derived from wild-type fibroblasts also reduced cellular growth rate, whereas
supplementation of IGF-1 to the conditioned medium obtained from <italic>Rarb</italic>-null
fibroblasts reversed the slow growth phenotype (<xref ref-type="fig" rid="f4">Figure 4E</xref>).
Taken together, these data indicate that in the absence of RAR&#x003b2;, reduced expression of IGF-1
and activity of its downstream signaling pathway contribute to attenuate EMT in
<italic>Rarb</italic>-null tumors.</p><fig id="f4" fig-type="figure" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Down regulation of the IGF1/AKT axis in Wnt1-induced <italic>Rarb</italic>-null
tumors.</title><p>(a) Western blot analysis of components of the IGF-1/AKT signaling axis in lysates derived from
MMTV-<italic>Wnt1</italic> and MMTV-<italic>Wnt1</italic>/<italic>Rarb</italic><sup>-/-</sup>
tumors. (b) Serum concentration of IGF-1 in <italic>Rarb</italic>-null and wild-type mice. N=5 for
each group. (c) IGF-1 concentrations in the supernatant collected from <italic>Rarb</italic>-null
CAFs in culture compared to the supernatant obtained from wild type fibroblasts. N=5 for each group.
(d) Effect of RA (100 nM) on the expression of <italic>Igf1</italic> mRNA from wild-type
fibroblasts. N=4 for each group. (e) Growth curves of tumor cells cultured in the presence of
conditioned media derived from wild-type (WT) or RAR&#x003b2;<sup>-/-</sup> mammary fibroblasts and
immunoneutralized with an antibody (Ab) against IGF-1 or supplemented with IGF-1.
*<italic>P</italic> &#x0003c; 0.05, ***<italic>P</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="nrs-12-004-g4"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The antitumor activities of retinoids and their receptors have been investigated extensively and
one of the receptors, RAR&#x003b2;, has been suggested to possess many of the functional
characteristics of a tumor suppressor [<xref rid="r13" ref-type="bibr">13</xref>]. However, previous
work from our laboratory showed that in the context of the whole organism, <italic>Rarb</italic> is
not a tumor suppressor, but rather that its presence is required for the full oncogenic potential of
<italic>Erbb2/neu</italic> [<xref rid="r16" ref-type="bibr">16</xref>]. Tissue recombination studies
indicated that it is the absence of RAR&#x003b2; in the tumor microenvironment, rather than the
status of <italic>Rarb</italic> in mammary epithelial cells, that affects the initiation and
progression of <italic>Erbb2/neu</italic>-induced mammary gland carcinoma. In the current study, we
monitored the influence of <italic>Rarb</italic> deletion on the induction of mammary tumors by the
<italic>Wnt1</italic> oncogene to test whether the absence of retinoid signaling via RAR&#x003b2;
affects mammary tumor formation driven by a different oncogenic pathway. As previously observed with
the MMTV-<italic>erbb2/neu</italic> model, ablation of <italic>Rarb</italic> in the
MMTV-<italic>Wnt1</italic> model showed extensive remodeling of the stroma during tumor progression
through suppression of the activation and trans-differentiation of CAFs, reduction in matrix
stiffness, decreased tumor angiogenesis and reduced inflammatory cell infiltration. Despite these
similarities, the molecular mechanism underlining the interactions by which <italic>Rarb</italic>
confers its effects on tumor cells is distinct between the two mouse models of human breast cancer.
Clinically, these results imply that modulation of RAR&#x003b2; activity could have important
applications to treat breast cancers of different cellular origin and/or driven by distinct
oncogenic pathways.</p><p>In the <italic>Wnt1</italic> model, oncogenic transformation has been proposed to target mammary
gland stem cells or early progenitor cells. Therefore, <italic>Wnt1</italic>-induced tumors are
morphologically composed of a variety of cell types, including distinct tumor luminal epithelial,
basal/myoepithelial cells and host-derived stroma cells [<xref rid="r27" ref-type="bibr">27</xref>-<xref rid="r29" ref-type="bibr">29</xref>]. Wnt1 ligand produced by tumor cells can
directly activate the surrounding stromal cells in a paracrine manner [<xref rid="r30" ref-type="bibr">30</xref>]. In return, stromal cells can affect tumor cells by expressing IGF-1, which
activates IGF1R signaling in tumor cells [<xref rid="r31" ref-type="bibr">31</xref>]. This important
molecular cross talk between tumor and stromal cells is severely weakened in the absence of
RAR&#x003b2;. Deletion of <italic>Rarb</italic> down-regulated Wnt1 signaling as indicated by
E-cadherin expression and nuclear localization of &#x003b2;-catenin resulting in lower IGF-1
expression in the stroma and suppression of the IGF-1/AKT axis in the tumor cells. Notably, reports
demonstrated the importance of Wnt1 signaling in mammary stroma of human breast cancer which has
been linked to EMT and poor clinical outcome [<xref rid="r32" ref-type="bibr">32</xref>-<xref rid="r34" ref-type="bibr">34</xref>].</p><p>Besides affecting stromal cells, Wnt1 ligand secreted by luminal epithelia can also target
myoepithelial cells [<xref rid="r30" ref-type="bibr">30</xref>]. A recent report indicates that the
<italic>Wnt1</italic>-driven tumor growth can be inhibited by a soluble Wnt receptor inhibitor
[<xref rid="r31" ref-type="bibr">31</xref>]. The mechanism through which this effect is mediated
involves the induction of IGFBP5, an antagonist of IGF signaling that has been shown to facilitate
tumor growth by paracrine communication. The regulation of IGFBP5 is mediated by the
&#x003b2;-catenin-dependent Wnt pathway. Strikingly, we observed that <italic>Igfbp5</italic> was
up-regulated about 2-fold in transcript levels while <italic>Igf1</italic> was down regulated in the
<italic>Rarb</italic>-null tumors. It has also been reported that overexpression of IGFBP5 results
in an increase in apoptotic cells in the mammary glands, whereas mice with mutant
<italic>Igfbp5</italic> exhibit a decrease in apoptotic cells and a delay in mammary gland
involution [<xref rid="r35" ref-type="bibr">35</xref>-<xref rid="r37" ref-type="bibr">37</xref>].
IGF-1 is a known growth and survival factor in mammary epithelial cells, and hyperactive IGF-1
signaling is found in various human tumors including breast cancer [<xref rid="r38" ref-type="bibr">38</xref>,<xref rid="r39" ref-type="bibr">39</xref>]. Moreover, IGF1R activation has been shown to
induce EMT by a PI3K/AKT-mediated mechanism and a concomitant increase in the expression of Snail
and suppression of E-cadherin expression [<xref rid="r40" ref-type="bibr">40</xref>-<xref rid="r45" ref-type="bibr">45</xref>]. In agreement with these reports, we observed increased and
decreased levels of E-cadherin and Snail proteins, respectively, as well as decrease cell
proliferation and more apoptosis in <italic>Rarb</italic>-null tumors. Accordingly, both suppression
of Wnt1 signaling pathway and repression of the IGF1/AKT axis in the absence of
<italic>Rarb</italic> have an important negative impact on CAF activation and EMT in the
<italic>Wnt1</italic>-induced tumors.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The failure of retinoid-based therapies to treat breast cancer led us and others to hypothesize
that retinoic acid receptor isoform might have distinct and perhaps antagonistic functions in
mammary gland development and in oncogenesis. Indeed, while activation or inhibition of the
RAR&#x003b1; isoform in mice are consistent with the anti-proliferative action of this receptor
[<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r46" ref-type="bibr">46</xref>], the activity
of the RAR&#x003b2; and RAR&#x003b3; suggests that these isoforms act as proto-oncogenes in the
context of the whole gland [<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r46" ref-type="bibr">46</xref>]. In this work, we extended these findings by demonstrating that
<italic>Rarb</italic> is crucial for the interaction between tumor cells and stromal cells. We found
that <italic>Rarb</italic> expression has an important impact on Wnt signaling in both tumor and
stromal cells. Specifically, inactivation of <italic>Rarb</italic> resulted in suppression of Wnt1
signaling which further inhibited the IGF-1/AKT/Snail/E-cadherin pathway and consequently repressed
EMT (<xref ref-type="fig" rid="f5">Figure 5</xref>). Since <italic>Wnt1</italic>-induced tumors in
the mouse resemble triple negative breast cancer or basal-like breast cancer in which the Wnt and
IGF-1 signaling pathways are known to be activated, this work suggests that specific RAR&#x003b2;
antagonists could have useful clinical application in the treatment of poor outcome breast
cancer.</p><fig id="f5" fig-type="figure" orientation="portrait" position="float"><label>Figure 5</label><caption><title><italic>Rarb</italic> is crucial for the interaction between tumor cells and stromal
cells.</title><p>Schematic representation of perturbed signaling pathways in <italic>Wnt1</italic>-induced tumors
and their microenvironments in wild-type and <italic>Rarb</italic><sup>-/-</sup> mice. Loss of
<italic>Rarb</italic> leads to remodeling of the stroma (bars), reduced Wnt-1 signaling in CAFs,
decreased IGF-1 levels and inhibition of EMT in the tumor as assessed by lower expression of Snail,
decreased and increased AKT and GSK-&#x003b2; phosphorylation, respectively.</p></caption><graphic xlink:href="nrs-12-004-g5"/></fig></sec><sec><title>Acknowledgements</title><p>We thank Carlo Ouellet for technical help with handling of the animals and Catherine R. Dufour
for assistance in the analysis of microarray expression datasets and preparation of the manuscript.
This work was funded by a Terry Fox New Frontiers Program Group Grant administered by the Canadian
Cancer Society Research Institute and by an operating grant from the Canadian Institutes of Health
Research (MOP-64275).</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>Competing Interests: The authors declare that they have no competing interests.</p></fn></fn-group><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duester</surname><given-names>G</given-names></name></person-group>: <article-title>Retinoic acid synthesis and signaling during early
organogenesis.</article-title>
<source>Cell</source>
<year>2008</year>, <volume>134</volume>:<fpage>921</fpage>-<lpage>931</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.09.002</pub-id><?supplied-pmid 18805086?><pub-id pub-id-type="pmid">18805086</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noy</surname><given-names>N</given-names></name></person-group>: <article-title>Between death and survival: retinoic acid in regulation of
apoptosis.</article-title>
<source>Annu Rev Nutr</source>
<year>2010</year>, <volume>30</volume>:<fpage>201</fpage>-<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.nutr.28.061807.155509</pub-id><?supplied-pmid 20415582?><pub-id pub-id-type="pmid">20415582</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maden</surname><given-names>M</given-names></name><name><surname>Hind</surname><given-names>M</given-names></name></person-group>: <article-title>Retinoic acid, a regeneration-inducing
molecule.</article-title>
<source>Dev Dyn</source>
<year>2003</year>, <volume>226</volume>:<fpage>237</fpage>-<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1002/dvdy.10222</pub-id><?supplied-pmid 12557202?><pub-id pub-id-type="pmid">12557202</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gigu&#x000e8;re</surname><given-names>V</given-names></name></person-group>: <article-title>Retinoic acid receptors and cellular retinoid binding
proteins: complex interplay in retinoid signaling.</article-title>
<source>Endocr Rev</source>
<year>1994</year>, <volume>15</volume>:<fpage>61</fpage>-<lpage>79</lpage>.<?supplied-pmid 8156940?><pub-id pub-id-type="pmid">8156940</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mark</surname><given-names>M</given-names></name><name><surname>Ghyselinck</surname><given-names>NB</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group>: <article-title>Function of retinoid nuclear receptors: lessons from genetic
and pharmacological dissections of the retinoic acid signaling pathway during mouse
embryogenesis.</article-title>
<source>Annu Rev Pharmacol Toxicol</source>
<year>2006</year>, <volume>46</volume>:<fpage>451</fpage>-<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.pharmtox.46.120604.141156</pub-id><?supplied-pmid 16402912?><pub-id pub-id-type="pmid">16402912</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenauer</surname><given-names>A</given-names></name><name><surname>Nervi</surname><given-names>C</given-names></name><name><surname>Davison</surname><given-names>K</given-names></name><name><surname>Lamph</surname><given-names>WW</given-names></name><name><surname>Mader</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>WH</given-names><suffix>Jr</suffix></name></person-group>.: <article-title>Estrogen receptor expression activates the transcriptional
and growth- inhibitory response to retinoids without enhanced retinoic acid receptor alpha
expression.</article-title>
<source>Cancer Res</source>
<year>1998</year>, <volume>58</volume>:<fpage>5110</fpage>-<lpage>5116</lpage>.<?supplied-pmid 9823320?><pub-id pub-id-type="pmid">9823320</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donato</surname><given-names>LJ</given-names></name><name><surname>Noy</surname><given-names>N</given-names></name></person-group>: <article-title>Suppression of mammary carcinoma growth by retinoic acid:
proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein
II signaling.</article-title>
<source>Cancer Res</source>
<year>2005</year>, <volume>65</volume>:<fpage>8193</fpage>-<lpage>8199</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1177</pub-id><?supplied-pmid 16166294?><pub-id pub-id-type="pmid">16166294</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donato</surname><given-names>LJ</given-names></name><name><surname>Suh</surname><given-names>JH</given-names></name><name><surname>Noy</surname><given-names>N</given-names></name></person-group>: <article-title>Suppression of mammary carcinoma cell growth by retinoic
acid: the cell cycle control gene Btg2 is a direct target for retinoic acid receptor
signaling.</article-title>
<source>Cancer Res</source>
<year>2007</year>, <volume>67</volume>:<fpage>609</fpage>-<lpage>615</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0989</pub-id><?supplied-pmid 17234770?><pub-id pub-id-type="pmid">17234770</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Uytingco</surname><given-names>MS</given-names></name><name><surname>Christakos</surname><given-names>S</given-names></name><name><surname>Wieder</surname><given-names>R</given-names></name></person-group>: <article-title>1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid
sensitize breast cancer cells to chemotherapy-induced cell death.</article-title>
<source>Cancer Res</source>
<year>2000</year>, <volume>60</volume>:<fpage>2040</fpage>-<lpage>2048</lpage>.<?supplied-pmid 10766196?><pub-id pub-id-type="pmid">10766196</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>RC</given-names></name><name><surname>Constantinou</surname><given-names>AI</given-names></name></person-group>: <article-title>Dietary retinoids and carotenoids in rodent models of mammary
tumorigenesis.</article-title>
<source>Breast Cancer Res Treat</source>
<year>1997</year>, <volume>46</volume>:<fpage>181</fpage>-<lpage>189</lpage>. <pub-id pub-id-type="doi">10.1023/A:1005995925246</pub-id><?supplied-pmid 9478273?><pub-id pub-id-type="pmid">9478273</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>M-O</given-names></name><name><surname>Wang</surname><given-names>H-G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Klaus</surname><given-names>M</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name><name><surname>Zhang</surname><given-names>X-K</given-names></name></person-group>: <article-title>Retinoic acid receptor &#x000df; mediates the
growth-inhibitory effects of retinoic acid by promoting apoptosis in human breast cancer
cells.</article-title>
<source>Mol Cell Biol</source>
<year>1996</year>, <volume>16</volume>:<fpage>1138</fpage>-<lpage>1149</lpage>.<?supplied-pmid 8622658?><pub-id pub-id-type="pmid">8622658</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontana</surname><given-names>JA</given-names></name><name><surname>Nervi</surname><given-names>C</given-names></name><name><surname>Shao</surname><given-names>ZM</given-names></name><name><surname>Jetten</surname><given-names>AM</given-names></name></person-group>: <article-title>Retinoid antagonism of estrogen-responsive transforming
growth factor a and pS2 gene expression in breast carcinoma cells.</article-title>
<source>Cancer Res</source>
<year>1992</year>, <volume>52</volume>:<fpage>3938</fpage>-<lpage>3945</lpage>.<?supplied-pmid 1319834?><pub-id pub-id-type="pmid">1319834</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>S</given-names></name><name><surname>Germain</surname><given-names>P</given-names></name><name><surname>Alvarez</surname><given-names>R</given-names></name><name><surname>Rodriguez-Barrios</surname><given-names>F</given-names></name><name><surname>Gronemeyer</surname><given-names>H</given-names></name><name><surname>de Lera</surname><given-names>AR</given-names></name></person-group>: <article-title>Structure, function and modulation of retinoic acid receptor
beta, a tumor suppressor.</article-title>
<source>Int J Biochem Cell Biol</source>
<year>2007</year>, <volume>39</volume>:<fpage>1406</fpage>-<lpage>1415</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2007.02.010</pub-id><?supplied-pmid 17433757?><pub-id pub-id-type="pmid">17433757</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiesa</surname><given-names>MD</given-names></name><name><surname>Passalacqua</surname><given-names>R</given-names></name><name><surname>Michiara</surname><given-names>M</given-names></name><name><surname>Franciosi</surname><given-names>V</given-names></name><name><surname>Di Costanzo</surname><given-names>F</given-names></name><name><surname>Bisagni</surname><given-names>G</given-names></name><name><surname>Camisa</surname><given-names>R</given-names></name><name><surname>Buti</surname><given-names>S</given-names></name><name><surname>Tomasello</surname><given-names>G</given-names></name><name><surname>Cocconi</surname><given-names>G</given-names></name></person-group>: <article-title>Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen
plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated
results of a phase II, prospective, randomised multicentre trial.</article-title>
<source>Acta Biomed</source>
<year>2007</year>, <volume>78</volume>:<fpage>204</fpage>-<lpage>209</lpage>.<?supplied-pmid 18330080?><pub-id pub-id-type="pmid">18330080</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singletary</surname><given-names>SE</given-names></name><name><surname>Atkinson</surname><given-names>EN</given-names></name><name><surname>Hoque</surname><given-names>A</given-names></name><name><surname>Sneige</surname><given-names>N</given-names></name><name><surname>Sahin</surname><given-names>AA</given-names></name><name><surname>Fritsche</surname><given-names>HA</given-names><suffix>Jr</suffix></name><name><surname>Lotan</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Hittelman</surname><given-names>WN</given-names></name><name><surname>Bevers</surname><given-names>TB</given-names></name><etal/></person-group>: <article-title>Phase II clinical trial of
N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast
neoplasia.</article-title>
<source>Clin Cancer Res</source>
<year>2002</year>, <volume>8</volume>:<fpage>2835</fpage>-<lpage>2842</lpage>.<?supplied-pmid 12231524?><pub-id pub-id-type="pmid">12231524</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Nugoli</surname><given-names>M</given-names></name><name><surname>Laferriere</surname><given-names>J</given-names></name><name><surname>Saleh</surname><given-names>SM</given-names></name><name><surname>Rodrigue-Gervais</surname><given-names>IG</given-names></name><name><surname>Saleh</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Hallett</surname><given-names>MT</given-names></name><name><surname>Muller</surname><given-names>WJ</given-names></name><name><surname>Gigu&#x000e8;re</surname><given-names>V</given-names></name></person-group>: <article-title>Stromal retinoic acid receptor &#x003b2; promotes mammary
gland tumorigenesis.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2011</year>, <volume>108</volume>:<fpage>774</fpage>-<lpage>779</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1011845108</pub-id><?supplied-pmid 21187396?><pub-id pub-id-type="pmid">21187396</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>E</given-names></name><name><surname>Ossowski</surname><given-names>L</given-names></name><name><surname>Bertran</surname><given-names>S</given-names></name><name><surname>Marzan</surname><given-names>C</given-names></name><name><surname>Farias</surname><given-names>EF</given-names></name></person-group>: <article-title>RARalpha1 control of mammary gland ductal morphogenesis and
Wnt1-tumorigenesis.</article-title>
<source>Breast Cancer Res</source>
<year>2010</year>, <volume>12</volume>:<fpage>R79</fpage>. <pub-id pub-id-type="doi">10.1186/bcr2724</pub-id><?supplied-pmid 20923554?><pub-id pub-id-type="pmid">20923554</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Pasceri</surname><given-names>P</given-names></name><name><surname>Conlon</surname><given-names>RA</given-names></name><name><surname>Rossant</surname><given-names>J</given-names></name><name><surname>Gigu&#x000e8;re</surname><given-names>V</given-names></name></person-group>: <article-title>Mice lacking all isoforms of retinoic acid receptor &#x000df;
develop normally and are susceptible to the teratogenic effects of retinoic acid.</article-title>
<source>Mech Dev</source>
<year>1995</year>, <volume>53</volume>:<fpage>61</fpage>-<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/0925-4773(95)00424-6</pub-id><?supplied-pmid 8555112?><pub-id pub-id-type="pmid">8555112</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>E</given-names></name><name><surname>Sucov</surname><given-names>HM</given-names></name><name><surname>Lee</surname><given-names>K-H</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group>: <article-title>Normal development and growth of mice carrying a targeted
disruption of the a1 retinoic acid receptor gene.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>1993</year>, <volume>90</volume>:<fpage>1590</fpage>-<lpage>1594</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.90.4.1590</pub-id><?supplied-pmid 7679509?><pub-id pub-id-type="pmid">7679509</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendelsohn</surname><given-names>C</given-names></name><name><surname>Mark</surname><given-names>M</given-names></name><name><surname>Doll&#x000e9;</surname><given-names>P</given-names></name><name><surname>Dierich</surname><given-names>A</given-names></name><name><surname>Gaub</surname><given-names>M-P</given-names></name><name><surname>Krust</surname><given-names>A</given-names></name><name><surname>Lampron</surname><given-names>C</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group>: <article-title>Retinoic acid receptor &#x000df;2 (RAR&#x000df;2) null mutant
mice appear normal.</article-title>
<source>Dev Biol</source>
<year>1994</year>, <volume>166</volume>:<fpage>246</fpage>-<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1006/dbio.1994.1311</pub-id><?supplied-pmid 7958449?><pub-id pub-id-type="pmid">7958449</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khramtsov</surname><given-names>AI</given-names></name><name><surname>Khramtsova</surname><given-names>GF</given-names></name><name><surname>Tretiakova</surname><given-names>M</given-names></name><name><surname>Huo</surname><given-names>D</given-names></name><name><surname>Olopade</surname><given-names>OI</given-names></name><name><surname>Goss</surname><given-names>KH</given-names></name></person-group>: <article-title>Wnt/beta-catenin pathway activation is enriched in basal-like
breast cancers and predicts poor outcome.</article-title>
<source>Am J Pathol</source>
<year>2010</year>, <volume>176</volume>:<fpage>2911</fpage>-<lpage>2920</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2010.091125</pub-id><?supplied-pmid 20395444?><pub-id pub-id-type="pmid">20395444</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>AH</given-names></name><name><surname>Howell</surname><given-names>A</given-names></name><name><surname>Howell</surname><given-names>SJ</given-names></name><name><surname>Clarke</surname><given-names>RB</given-names></name></person-group>: <article-title>Origins of breast cancer subtypes and therapeutic
implications.</article-title>
<source>Nat Clin Pract Oncol</source>
<year>2007</year>, <volume>4</volume>:<fpage>516</fpage>-<lpage>525</lpage>. <pub-id pub-id-type="doi">10.1038/ncponc0908</pub-id><?supplied-pmid 17728710?><pub-id pub-id-type="pmid">17728710</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howe</surname><given-names>LR</given-names></name><name><surname>Brown</surname><given-names>AM</given-names></name></person-group>: <article-title>Wnt signaling and breast cancer.</article-title>
<source>Cancer Biol Ther</source>
<year>2004</year>, <volume>3</volume>:<fpage>36</fpage>-<lpage>41</lpage>. <pub-id pub-id-type="doi">10.4161/cbt.3.1.561</pub-id><?supplied-pmid 14739782?><pub-id pub-id-type="pmid">14739782</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukamoto</surname><given-names>AS</given-names></name><name><surname>Grosschedl</surname><given-names>R</given-names></name><name><surname>Guzman</surname><given-names>RC</given-names></name><name><surname>Parslow</surname><given-names>T</given-names></name><name><surname>Varmus</surname><given-names>HE</given-names></name></person-group>: <article-title>Expression of the int-1 gene in transgenic mice is associated
with mammary gland hyperplasia and adenocarcinomas in male and female mice.</article-title>
<source>Cell</source>
<year>1988</year>, <volume>55</volume>:<fpage>619</fpage>-<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(88)90220-6</pub-id><?supplied-pmid 3180222?><pub-id pub-id-type="pmid">3180222</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>N</given-names></name><name><surname>Hughes</surname><given-names>B</given-names></name><name><surname>Bigras</surname><given-names>E</given-names></name><name><surname>Shoubridge</surname><given-names>E</given-names></name><name><surname>Hekimi</surname><given-names>S</given-names></name></person-group>: <article-title>Evolutionary conservation of the clk-1-dependent mechanism of
longevity: loss of mclk1 increases cellular fitness and lifespan in mice.</article-title>
<source>Genes Dev</source>
<year>2005</year>, <volume>19</volume>:<fpage>2424</fpage>-<lpage>2434</lpage>. <pub-id pub-id-type="doi">10.1101/gad.1352905</pub-id><?supplied-pmid 16195414?><pub-id pub-id-type="pmid">16195414</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radisky</surname><given-names>DC</given-names></name><name><surname>Kenny</surname><given-names>PA</given-names></name><name><surname>Bissell</surname><given-names>MJ</given-names></name></person-group>: <article-title>Fibrosis and cancer: do myofibroblasts come also from
epithelial cells via EMT?</article-title>
<source>J Cell Biochem</source>
<year>2007</year>, <volume>101</volume>:<fpage>830</fpage>-<lpage>839</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.21186</pub-id><?supplied-pmid 17211838?><pub-id pub-id-type="pmid">17211838</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prat</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Karginova</surname><given-names>O</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Livasy</surname><given-names>C</given-names></name><name><surname>Herschkowitz</surname><given-names>JI</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group>: <article-title>Phenotypic and molecular characterization of the claudin-low
intrinsic subtype of breast cancer.</article-title>
<source>Breast Cancer Res</source>
<year>2010</year>, <volume>12</volume>:<fpage>R68</fpage>. <pub-id pub-id-type="doi">10.1186/bcr2635</pub-id><?supplied-pmid 20813035?><pub-id pub-id-type="pmid">20813035</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herschkowitz</surname><given-names>JI</given-names></name><name><surname>Simin</surname><given-names>K</given-names></name><name><surname>Weigman</surname><given-names>VJ</given-names></name><name><surname>Mikaelian</surname><given-names>I</given-names></name><name><surname>Usary</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Rasmussen</surname><given-names>KE</given-names></name><name><surname>Jones</surname><given-names>LP</given-names></name><name><surname>Assefnia</surname><given-names>S</given-names></name><name><surname>Chandrasekharan</surname><given-names>S</given-names></name><etal/></person-group>: <article-title>Identification of conserved gene expression features
between murine mammary carcinoma models and human breast tumors.</article-title>
<source>Genome Biol</source>
<year>2007</year>, <volume>8</volume>:<fpage>R76</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2007-8-5-r76</pub-id><?supplied-pmid 17493263?><pub-id pub-id-type="pmid">17493263</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XR</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Goode</surname><given-names>EL</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name><name><surname>Nevanlinna</surname><given-names>H</given-names></name><name><surname>Milne</surname><given-names>RL</given-names></name><name><surname>Gaudet</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>MK</given-names></name><name><surname>Broeks</surname><given-names>A</given-names></name><name><surname>Cox</surname><given-names>A</given-names></name><etal/></person-group>: <article-title>Associations of breast cancer risk factors with tumor
subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.</article-title>
<source>J Natl Cancer Inst</source>
<year>2011</year>, <volume>103</volume>:<fpage>250</fpage>-<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djq526</pub-id><?supplied-pmid 21191117?><pub-id pub-id-type="pmid">21191117</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YC</given-names></name><name><surname>Clark</surname><given-names>RJ</given-names></name><name><surname>Ranheim</surname><given-names>EA</given-names></name><name><surname>Alexander</surname><given-names>CM</given-names></name></person-group>: <article-title>Wnt1 expression induces short-range and long-range cell
recruitments that modify mammary tumor development and are not induced by a cell-autonomous
beta-catenin effector.</article-title>
<source>Cancer Res</source>
<year>2008</year>, <volume>68</volume>:<fpage>10145</fpage>-<lpage>10153</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2992</pub-id><?supplied-pmid 19074881?><pub-id pub-id-type="pmid">19074881</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>BY</given-names></name><name><surname>Soloviev</surname><given-names>I</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>P</given-names></name><name><surname>Ernst</surname><given-names>JA</given-names></name><name><surname>Polakis</surname><given-names>P</given-names></name><name><surname>Sakanaka</surname><given-names>C</given-names></name></person-group>: <article-title>Mammary tumor regression elicited by Wnt signaling inhibitor
requires IGFBP5.</article-title>
<source>Cancer Res</source>
<year>2012</year>, <volume>72</volume>:<fpage>1568</fpage>-<lpage>1578</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3668</pub-id><?supplied-pmid 22307840?><pub-id pub-id-type="pmid">22307840</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Broaddus</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Naora</surname><given-names>H</given-names></name></person-group>: <article-title>Deregulation of the HOXA10 homeobox gene in endometrial
carcinoma: role in epithelial-mesenchymal transition.</article-title>
<source>Cancer Res</source>
<year>2006</year>, <volume>66</volume>:<fpage>889</fpage>-<lpage>897</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2828</pub-id><?supplied-pmid 16424022?><pub-id pub-id-type="pmid">16424022</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AY</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>You</surname><given-names>L</given-names></name><name><surname>Dadfarmay</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Mazieres</surname><given-names>J</given-names></name><name><surname>Mikami</surname><given-names>I</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name><name><surname>Jablons</surname><given-names>DM</given-names></name></person-group>: <article-title>Expression of the secreted frizzled-related protein gene
family is downregulated in human mesothelioma.</article-title>
<source>Oncogene</source>
<year>2004</year>, <volume>23</volume>:<fpage>6672</fpage>-<lpage>6676</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1207881</pub-id><?supplied-pmid 15221014?><pub-id pub-id-type="pmid">15221014</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finak</surname><given-names>G</given-names></name><name><surname>Bertos</surname><given-names>N</given-names></name><name><surname>Pepin</surname><given-names>F</given-names></name><name><surname>Sadekova</surname><given-names>S</given-names></name><name><surname>Souleimanova</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Omeroglu</surname><given-names>G</given-names></name><name><surname>Meterissian</surname><given-names>S</given-names></name><name><surname>Omeroglu</surname><given-names>A</given-names></name><etal/></person-group>: <article-title>Stromal gene expression predicts clinical outcome in
breast cancer.</article-title>
<source>Nat Med</source>
<year>2008</year>, <volume>14</volume>:<fpage>518</fpage>-<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1038/nm1764</pub-id><?supplied-pmid 18438415?><pub-id pub-id-type="pmid">18438415</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonner</surname><given-names>E</given-names></name><name><surname>Barber</surname><given-names>MC</given-names></name><name><surname>Allan</surname><given-names>GJ</given-names></name><name><surname>Beattie</surname><given-names>J</given-names></name><name><surname>Webster</surname><given-names>J</given-names></name><name><surname>Whitelaw</surname><given-names>CB</given-names></name><name><surname>Flint</surname><given-names>DJ</given-names></name></person-group>: <article-title>Insulin-like growth factor binding protein-5 (IGFBP-5)
induces premature cell death in the mammary glands of transgenic mice.</article-title>
<source>Development</source>
<year>2002</year>, <volume>129</volume>:<fpage>4547</fpage>-<lpage>4557</lpage>.<?supplied-pmid 12223411?><pub-id pub-id-type="pmid">12223411</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Hoang</surname><given-names>B</given-names></name><name><surname>Schuller</surname><given-names>AG</given-names></name><name><surname>Cominski</surname><given-names>TP</given-names></name><name><surname>Hsu</surname><given-names>MS</given-names></name><name><surname>Wood</surname><given-names>TL</given-names></name><name><surname>Pintar</surname><given-names>JE</given-names></name></person-group>: <article-title>Delayed mammary gland involution in mice with mutation of the
insulin-like growth factor binding protein 5 gene.</article-title>
<source>Endocrinology</source>
<year>2007</year>, <volume>148</volume>:<fpage>2138</fpage>-<lpage>2147</lpage>. <pub-id pub-id-type="doi">10.1210/en.2006-0041</pub-id><?supplied-pmid 17255210?><pub-id pub-id-type="pmid">17255210</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshman</surname><given-names>E</given-names></name><name><surname>Green</surname><given-names>KA</given-names></name><name><surname>Flint</surname><given-names>DJ</given-names></name><name><surname>White</surname><given-names>A</given-names></name><name><surname>Streuli</surname><given-names>CH</given-names></name><name><surname>Westwood</surname><given-names>M</given-names></name></person-group>: <article-title>Insulin-like growth factor binding protein 5 and apoptosis in
mammary epithelial cells.</article-title>
<source>J Cell Sci</source>
<year>2003</year>, <volume>116</volume>:<fpage>675</fpage>-<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.00263</pub-id><?supplied-pmid 12538768?><pub-id pub-id-type="pmid">12538768</pub-id></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RA</given-names></name><name><surname>Moorehead</surname><given-names>RA</given-names></name></person-group>: <article-title>The impact of transgenic IGF-IR overexpression on mammary
development and tumorigenesis.</article-title>
<source>J Mammary Gland Biol Neoplasia</source>
<year>2008</year>, <volume>13</volume>:<fpage>407</fpage>-<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1007/s10911-008-9097-1</pub-id><?supplied-pmid 19002570?><pub-id pub-id-type="pmid">19002570</pub-id></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lann</surname><given-names>D</given-names></name><name><surname>LeRoith</surname><given-names>D</given-names></name></person-group>: <article-title>The role of endocrine insulin-like growth factor-I and
insulin in breast cancer.</article-title>
<source>J Mammary Gland Biol Neoplasia</source>
<year>2008</year>, <volume>13</volume>:<fpage>371</fpage>-<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1007/s10911-008-9100-x</pub-id><?supplied-pmid 19030972?><pub-id pub-id-type="pmid">19030972</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irie</surname><given-names>HY</given-names></name><name><surname>Pearline</surname><given-names>RV</given-names></name><name><surname>Grueneberg</surname><given-names>D</given-names></name><name><surname>Hsia</surname><given-names>M</given-names></name><name><surname>Ravichandran</surname><given-names>P</given-names></name><name><surname>Kothari</surname><given-names>N</given-names></name><name><surname>Natesan</surname><given-names>S</given-names></name><name><surname>Brugge</surname><given-names>JS</given-names></name></person-group>: <article-title>Distinct roles of Akt1 and Akt2 in regulating cell migration
and epithelial-mesenchymal transition.</article-title>
<source>J Cell Biol</source>
<year>2005</year>, <volume>171</volume>:<fpage>1023</fpage>-<lpage>1034</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200505087</pub-id><?supplied-pmid 16365168?><pub-id pub-id-type="pmid">16365168</pub-id></mixed-citation></ref><ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Litzenburger</surname><given-names>BC</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Delgado</surname><given-names>DA</given-names></name><name><surname>Grabiner</surname><given-names>BC</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Lewis</surname><given-names>MT</given-names></name><name><surname>Gottardis</surname><given-names>MM</given-names></name><name><surname>Wong</surname><given-names>TW</given-names></name><name><surname>Attar</surname><given-names>RM</given-names></name><etal/></person-group>: <article-title>Constitutively active type I insulin-like growth
factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells
and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and
snail.</article-title>
<source>Mol Cell Biol</source>
<year>2007</year>, <volume>27</volume>:<fpage>3165</fpage>-<lpage>3175</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.01315-06</pub-id><?supplied-pmid 17296734?><pub-id pub-id-type="pmid">17296734</pub-id></mixed-citation></ref><ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>SL</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name></person-group>: <article-title>Divergent roles for IRS-1 and IRS-2 in breast cancer
metastasis.</article-title>
<source>Cell Cycle</source>
<year>2007</year>, <volume>6</volume>:<fpage>631</fpage>-<lpage>637</lpage>. <pub-id pub-id-type="doi">10.4161/cc.6.6.3987</pub-id><?supplied-pmid 17361103?><pub-id pub-id-type="pmid">17361103</pub-id></mixed-citation></ref><ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savagner</surname><given-names>P</given-names></name><name><surname>Yamada</surname><given-names>KM</given-names></name><name><surname>Thiery</surname><given-names>JP</given-names></name></person-group>: <article-title>The zinc-finger protein slug causes desmosome dissociation,
an initial and necessary step for growth factor-induced epithelial-mesenchymal
transition.</article-title>
<source>J Cell Biol</source>
<year>1997</year>, <volume>137</volume>:<fpage>1403</fpage>-<lpage>1419</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.137.6.1403</pub-id><?supplied-pmid 9182671?><pub-id pub-id-type="pmid">9182671</pub-id></mixed-citation></ref><ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>MA</given-names></name></person-group>: <article-title>The snail superfamily of zinc-finger transcription
factors.</article-title>
<source>Nat Rev Mol Cell Biol</source>
<year>2002</year>, <volume>3</volume>:<fpage>155</fpage>-<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1038/nrm757</pub-id><?supplied-pmid 11994736?><pub-id pub-id-type="pmid">11994736</pub-id></mixed-citation></ref><ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrallo-Gimeno</surname><given-names>A</given-names></name><name><surname>Nieto</surname><given-names>MA</given-names></name></person-group>: <article-title>The Snail genes as inducers of cell movement and survival:
implications in development and cancer.</article-title>
<source>Development</source>
<year>2005</year>, <volume>132</volume>:<fpage>3151</fpage>-<lpage>3161</lpage>. <pub-id pub-id-type="doi">10.1242/dev.01907</pub-id><?supplied-pmid 15983400?><pub-id pub-id-type="pmid">15983400</pub-id></mixed-citation></ref><ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Bertran</surname><given-names>S</given-names></name><name><surname>Samuels</surname><given-names>TA</given-names></name><name><surname>Mira-y-Lopez</surname><given-names>R</given-names></name><name><surname>Farias</surname><given-names>EF</given-names></name></person-group>: <article-title>Mechanism of inhibition of MMTV-neu and MMTV-Wnt1 induced
mammary oncogenesis by RARalpha agonist AM580.</article-title>
<source>Oncogene</source>
<year>2010</year>, <volume>29</volume>:<fpage>3665</fpage>-<lpage>3676</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2010.119</pub-id><?supplied-pmid 20453882?><pub-id pub-id-type="pmid">20453882</pub-id></mixed-citation></ref></ref-list></back></article>
